Prevalence of cardiac abnormalities and heart failure in unselected out-patients with type 2 diabetes mellitus and associated clinical factors: Real-world evidence from an Indian registry

被引:1
|
作者
Rajput, Rajesh [1 ]
Mohan, J. C. [2 ]
Sawhney, J. P. S. [3 ]
Dalal, Jamshed [4 ]
Mullasari, Ajit [5 ]
Vasnawala, Hardik [6 ]
Kumar, Amit [6 ]
Hs, Bharath [6 ]
Sarda, Shital [6 ]
机构
[1] PGIMS, Rohtak, India
[2] Jaipur Golden Hosp, Inst Heart & Vasc Dis, Sect 3, New Delhi, India
[3] Sir Ganga Ram Hosp, Delhi, India
[4] Kokilaben Dhirubhai Ambani Hosp, Mumbai, India
[5] MMM Hosp, Chennai, India
[6] AstraZeneca Pharm India Ltd, Med Affairs, Kochi, India
关键词
2-D echocardiography; Heart failure; Left ventricular dysfunction; Type 2 diabetes mellitus; LEFT-VENTRICULAR DYSFUNCTION; EUROPEAN-ASSOCIATION; AMERICAN-SOCIETY; CHAMBER QUANTIFICATION; ECHOCARDIOGRAPHY; RECOMMENDATIONS; GUIDELINES; UPDATE;
D O I
10.1016/j.ihj.2023.10.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Type 2 diabetes mellitus (T2DM) is known to be associated with development of left ventricular (LV) dysfunction and heart failure (HF). The study aimed to determine the prevalence of LV dysfunction and HF in unselected out-patients with T2DM with no previous cardiac history and to correlate LV dysfunction and HF with demographic and comorbid characteristics.Methods: This cross-sectional study conducted at 27 centers in India captured demographic and clinical data through electronic case record forms. B-type natriuretic peptide of >105 pg/mL was used to diagnose HF and two-dimensional echocardiography was used to assess LV dysfunction.Results: Of the 615 patients, 54.3 % (n = 334) were males; mean age was 57.4 +/- 10.48 years. More than one-third of the patients had T2DM duration of >10 years (n = 238; 38.7 %), with hypertension as the most prevalent comorbidity (n = 372, 78.6 %). Approximately 61.3 % of the patients had LV hypertrophy. The mean LV mass was 135.0 +/- 56.16 g (95 % CI 130.28, 139.70). The prevalence of any type of LV dysfunction, including systolic or diastolic dysfunction and HF was 55 % (95 % CI 51.0, 59.0) and 10 % (95 % CI 7.0, 12.0), respectively. A negligible but statistically significant correlation was observed between LV dysfunction and T2DM duration (p = 0.011), alongside HF and age (p < 0.0001).Conclusion: Real-world data from this registry from India demonstrates a substantial burden of LV dysfunction and HF in individuals with T2DM in India. It is imperative to formulate strategies for early identification of LV dysfunction in individuals with T2DM for prevention and consequent management of HF.
引用
收藏
页码:436 / 442
页数:7
相关论文
共 50 条
  • [31] Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
    Li, Qian
    Chitnis, Abhishek
    Hammer, Mette
    Langer, Jakob
    DIABETES THERAPY, 2014, 5 (02) : 579 - 590
  • [32] Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
    Qian Li
    Abhishek Chitnis
    Mette Hammer
    Jakob Langer
    Diabetes Therapy, 2014, 5 : 579 - 590
  • [33] Prevalence of Cognitive Decline in Type 2 Diabetes Mellitus Patients: A Real-World Cross-Sectional Study in Mysuru, India
    Kinattingal, Nabeel
    Mehdi, Seema
    Undela, Krishna
    Wani, Shahid Ud Din
    Almuqbil, Mansour
    Alshehri, Sultan
    Shakeel, Faiyaz
    Imam, Mohammad T.
    Manjula, Santhepete N.
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (03):
  • [34] Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials
    Liang, Bo
    Gu, Ning
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2022, 19 (07): : 1118 - 1121
  • [35] Real-World Clinical Outcomes Associated with Canagliflozin in Patients Aged 65 Years and Older with Type 2 Diabetes Mellitus in Spain: The Old Real-Wecan Study
    Gargallo-Fernandez, Manuel A.
    Sanz-Pastor, Alba Galdon
    Anton-Bravo, Teresa
    Brito-Sanfiel, Miguel
    Wong-Cruz, Jaime
    Gorgojo-Martinez, Juan J.
    DIABETOLOGY, 2021, 2 (03): : 165 - 175
  • [36] REAL-WORLD TREATMENT PATTERN IN COMMUNITY PATIENTS WITH TYPE-2 DIABETES: EVIDENCE FROM SHANGHAI, CHINA
    Gao, Y.
    Chen, L.
    Fang, H.
    Xu, D.
    Xuan, J.
    Liu, B.
    VALUE IN HEALTH, 2016, 19 (07) : A680 - A680
  • [37] Eligibility and Awareness Regarding Metabolic Surgery in Patients With Type 2 Diabetes Mellitus in the Real-World Clinical Setting; Estimate of Possible Diabetes Remission
    Koliaki, Chrysi
    Tzeravini, Evangelia
    Papachristoforou, Eleftheria
    Severi, Ioanna
    El Deik, Elina
    Karaolia, Melina
    Noutsou, Marina
    Thanopoulou, Anastasia
    Kountouri, Aikaterini
    Balampanis, Konstantinos
    Lambadiari, Vaia
    Tentolouris, Nicholas
    Kokkinos, Alexander
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [38] Real-World Multicenter Registry to Determine Management and Quality of Care of Patients with Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases in China (iCaReMe China)
    Cai, Xiaoling
    Yang, Wenjia
    Feng, Bo
    Ji, Qiuhe
    Liu, Ming
    Li, Yanbing
    Tong, Nanwei
    Sun, Ningling
    Zhao, Minghui
    Ji, Linong
    ADVANCES IN THERAPY, 2025, 42 (03) : 1600 - 1609
  • [39] Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study
    He, Siyao
    Qian, Xin
    Chen, Yanyan
    Shen, Xiaoxia
    Zhang, Bo
    Chen, Xiaoping
    Xu, Xiangjin
    Li, Guangwei
    JOURNAL OF DIABETES RESEARCH, 2021, 2021
  • [40] Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population
    Li, Weijia
    Katamreddy, Adarsh
    Kataria, Rachna
    Myerson, Merle L.
    Taub, Cynthia C.
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (01) : 53 - 62